ArticleInternational journal of vascular medicine2026
Serum Activin A Level and 1-Year Mortality in Atrial Septal Defect-Associated Pulmonary Artery Hypertension: A Case-Control Study From the COHARD-PH Registry.
Article in International journal of vascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Activin A Level and 1-Year Mortality in Atrial Septal Defect-Associated Pulmonary Artery Hypertension: A Case-Control Study From the COHARD-PH Registry.International journal of vascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum activin A level is a promising prognostic biomarker for pulmonary artery hypertension (PAH). In this study, we aim to investigate serum activin A levels and their associations with 1-year mortality in atrial septal defect (ASD)-associated PAH patients. Methods: This was a case-control study of adult Indonesian patients diagnosed with ASD-PAH from the COHARD-PH registry. Cases were subjects deceased in a 1-year follow-up, whereas controls were those survived. Serum activin A was measured at the index of diagnosis. The demographics, clinical parameters, hemodynamic, and mortality data were retrieved from the registry database up to a 1-year follow-up period. These data were compared and analyzed between the case and control groups. Results: From the 1-year follow-up data, 44 cases (deceased group) and 102 controls (survived group) were identified. The deceased group had significant lower bodyweight ( Conclusion: Serum activin A level did not associate with 1-year mortality in adult patients with ASD-associated PAH.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.